McLaughlin Kevin F
- SEC CIK
- 0001214938
In the past year, 1 open-market purchase filing worth $125.0K and 4 sale filings worth $1.05M.
Current role at each company
- VCEL Vericel CorpDirectoras of Aug 14, 2026
- IVVD Invivyd, Inc.Directoras of May 21, 2026
- DBTX Decibel Therapeutics, Inc.Directoras of Sep 25, 2023
- XLRN Acceleron Pharma IncSVP, CFO and Treasureras of Nov 22, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $125.0K
- 1 filing
- Sold
- $1.05M
- 4 filings
- Net
- −$929.2K
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists McLaughlin Kevin F as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VCEL Vericel Corp
Director9 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 9, 2024 (view filing) | Aug 7 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $45.94 | −$321.6K | −37.0%11.9K after | 2 lots10b5-1 |
| Nov 15, 2024 (view filing) | Nov 13 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $55.54 | −$388.8K | −37.0%11.9K after | 10b5-1 |
| Feb 14, 2025 (view filing) | Feb 12 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $55.46 | −$388.3K | −37.0%11.9K after | 2 lots10b5-1 |
| May 9, 2025 (view filing) | May 7 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $39.98 | −$279.9K | −31.7%15.1K after | 10b5-1 |
| Aug 8, 2025 (view filing) | Aug 6 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $35.92 | −$251.4K | −31.7%15.1K after | 10b5-1 |
| Nov 12, 2025 (view filing) | Nov 10 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $38.59 | −$270.1K | −31.7%15.1K after | 10b5-1 |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $34.66 | −$242.6K | −31.7%15.1K after | 10b5-1 |
| May 15, 2026 (view filing) | May 13 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $32.83 | −$229.8K | −27.7%18.3K after | 2 lots10b5-1 |
| Aug 14, 2026 (view filing)4:05 PM ET | Aug 12 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $44.53 | −$311.7K | −27.7%18.3K after | 10b5-1 |
IVVD Invivyd, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 20, 2025 (view filing) | Nov 19 | 1 day | McLaughlin Kevin FDirector | PPurchase | +50.0K | $2.50 | +$125.0K | New position50.0K after |
XLRN Acceleron Pharma Inc
SVP, CFO and Treasurer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2021 (view filing) | Sep 23-24 | 1 day | McLaughlin Kevin FSVP, CFO and Treasurer | SSale | −25.0K | $160.33 | −$4.01M | −70.1%10.7K after | 3 lots |